How Does Survodutide Work? Mechanism of Action, Per the Research

Survodutide, also identified in trial reports by its development code BI 456906, is described in the published pharmacology literature as a dual glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) agonist designed for once-weekly subcutaneous administration (PMID 38330987). Reviews of emerging obesity pharmacotherapy grouped it with the unimolecular multi-receptor agonists, a class in which one engineered peptide activates more than one entero-pancreatic hormone receptor rather than combining separate drugs (PMID 39952695).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, including investigational or prescription-only products. Survodutide is a prescription-track medicine that has been evaluated in randomised clinical trials rather than a consumer product, and nothing below describes how it should be used, scheduled or dosed.

The two receptor targets

The GLP-1 receptor

The GLP-1 receptor is a class B G-protein-coupled receptor expressed on pancreatic beta cells, in regions of the hypothalamus and hindbrain, and in several peripheral tissues. Reviews of the GLP-1 medicine class described receptor activation as coupling to Gs proteins, stimulating adenylate cyclase and raising intracellular cyclic AMP, which in beta cells amplifies glucose-dependent insulin secretion and in the central nervous system engages circuits associated with satiety and reduced food intake (PMID 38843460). A broader review of novel GLP-1-based medicines for type 2 diabetes and obesity summarised the same canonical pathway alongside slowed gastric emptying and suppression of inappropriately elevated postprandial glucagon as the established peripheral components of GLP-1 receptor pharmacology (PMID 41054801).

The glucagon receptor

The glucagon receptor is expressed most densely on hepatocytes and also in adipose tissue, kidney and heart. A mechanism-focused review of GLP-1 receptor agonists and glucagon/GIP/GLP-1 dual and triple agonists in metabolic dysfunction-associated steatotic liver disease described glucagon receptor agonism as acting through hepatic cyclic AMP signalling to increase fatty-acid oxidation and reduce hepatic lipid accumulation, with additional effects on whole-body energy expenditure (PMID 40364529). A separate review covering GLP-1, GIP/GLP-1 and GCGR/GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis set out the same rationale: adding glucagon receptor activity is intended to target the liver directly rather than relying only on weight loss (PMID 39735270).

Why combining the two receptors is the point

Glucagon on its own raises hepatic glucose output, which historically made glucagon receptor agonism an unattractive strategy in metabolic disease. The pharmacological argument described in class reviews is that the insulinotropic and glucose-lowering actions of simultaneous GLP-1 receptor agonism are expected to counterbalance that glycaemic liability, allowing the catabolic, energy-expenditure and hepatic-lipid actions of glucagon to be used while glucose control is maintained (PMID 39735270). A review of entero-pancreatic hormone combinations for adults with type 2 diabetes framed dual and triple agonists as an attempt to recruit complementary hormone pathways within a single molecule, with survodutide cited among the glucagon-containing combinations under clinical investigation (PMID 38753454).

Receptor, signal and reported physiology at a glance

What is established mechanism and what is still proposed

It is worth separating the two tiers. The established tier is receptor-level: survodutide is characterised in the trial and review literature as an agonist at both the GLP-1 and glucagon receptors, and the downstream consequences of activating each receptor individually are long-standing textbook pharmacology summarised in class reviews (PMID 41054801). The proposed tier concerns how much of any clinical effect is attributable to the glucagon arm specifically, how much to the GLP-1 arm, and how much to weight loss itself. Mechanistic reviewers noted that much of the evidence for glucagon-driven increases in energy expenditure and direct hepatic fat oxidation comes from cell-based assays and rodent models rather than from human mechanistic studies, and that attribution in people remains inferential (PMID 40364529). Readers should treat animal and in-vitro findings as hypothesis-generating, not as demonstrated human physiology.

What clinical trials reported about the mechanism in people

Obesity

A randomised, double-blind, placebo-controlled phase 2 dose-finding trial of survodutide in adults with obesity escalated weekly subcutaneous doses up to 4.8 mg and reported significantly greater mean reductions in body weight than placebo at 46 weeks, which the investigators interpreted as consistent with dual glucagon and GLP-1 receptor agonism (PMID 38330987). A subsequent trial of once-weekly survodutide for the treatment of adults with obesity extended the clinical programme and reported body-weight outcomes versus placebo (PMID 42253238). A clinical overview of weight-management treatment in obesity placed survodutide among the dual-agonist agents whose development is being followed in this therapeutic area (PMID 40865172).

Liver endpoints

A phase 2 randomised trial of survodutide in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and fibrosis reported higher rates of histological improvement in steatohepatitis without worsening of fibrosis with survodutide than with placebo after 48 weeks of treatment (PMID 38847460). Researchers conducting a systematic review and network meta-analysis comparing pharmacological therapies for fibrosis regression and steatohepatitis resolution included glucagon/GLP-1 dual agonism among the strategies evaluated across trials (PMID 39903735). Reviewers have argued that liver histology findings are the kind of endpoint that could, in principle, reflect the glucagon-receptor component rather than weight loss alone, though they described this as a mechanistic hypothesis requiring dedicated study (PMID 39735270).

Body-composition questions raised in the literature

Because glucagon receptor agonism is catabolic, body composition has attracted mechanistic interest. A review of the impact of weight loss on fat-free mass, muscle, bone and haematopoiesis discussed emerging pharmacotherapies that aim at fat reduction with lean-mass preservation and noted that substantial pharmacological weight loss is generally accompanied by some loss of fat-free mass, making compartment-specific measurement important in future trials (PMID 39481534). That review framed lean-mass preservation as an open research question across the class rather than an established property of any single agent (PMID 39481534).

How the mechanism differs from single- and other dual-agonist designs

• GLP-1 receptor agonists alone act on one receptor; class reviews attributed their glycaemic and weight effects to insulinotropic, gastric and central appetite pathways (PMID 38843460).
• GIP/GLP-1 dual agonists add a different incretin receptor rather than a catabolic one, and reviews discussed them separately from glucagon-containing molecules (PMID 41054801).
• GCGR/GLP-1 dual agonists such as survodutide are distinguished in the literature by the addition of hepatic and energy-expenditure pathways through the glucagon receptor (PMID 39735270).
• Triple agonists combine all three receptor activities and were reviewed alongside dual agents in the MASLD mechanism literature (PMID 40364529).

Tolerability and Mechanism-Linked Effects: What Studies Report

Several of the adverse effects described for this class are plausibly downstream of the same receptor signalling that produces the intended physiology. In the phase 2 dose-finding trial in obesity, the most frequently reported adverse events were gastrointestinal, including nausea, vomiting and constipation, and they occurred more often with survodutide than with placebo, with dose escalation used to manage tolerability (PMID 38330987). The phase 2 trial in steatohepatitis similarly reported gastrointestinal adverse events as the most common class of events among participants receiving survodutide (PMID 38847460). A broader review of the efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity described gastrointestinal intolerance as the dominant tolerability issue for the class and discussed monitoring considerations that remain the responsibility of a prescribing clinician (PMID 38843460). A systematic review of emerging obesity pharmacotherapies likewise catalogued gastrointestinal events across investigational multi-receptor agonists (PMID 39952695).

Limits of the current mechanistic picture

1. Attribution is unresolved. No cited trial isolated the glucagon arm from the GLP-1 arm in humans, so the relative contribution of each receptor to weight or liver outcomes is inferred rather than measured (PMID 40364529).
2. Trial duration is finite. The phase 2 obesity trial ran to 46 weeks and the steatohepatitis trial to 48 weeks, so longer-term mechanistic consequences were outside their scope (PMID 38330987, PMID 38847460).
3. Comparative data are indirect. Network meta-analysis in steatohepatitis pooled across trials with differing populations and designs, which the authors treated as a limitation on cross-agent conclusions (PMID 39903735).
4. The development programme is ongoing. Reviews describe survodutide as an investigational agent within an evolving landscape rather than a settled therapy (PMID 40865172).

In summary, the mechanism of survodutide as described in the published record is dual receptor agonism: GLP-1 receptor signalling associated with insulin secretion, gastric emptying and appetite pathways, combined with glucagon receptor signalling associated with hepatic lipid handling and energy expenditure (PMID 41054801). The study results summarised above come from randomised trials and reviews, and researchers reported both the intended metabolic effects and the gastrointestinal tolerability profile of the class. Any question about whether a medicine of this kind is appropriate for an individual is a clinical question for a licensed prescriber.

References

• Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial (The Lancet Diabetes & Endocrinology, 2024)
• A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (The New England Journal of Medicine, 2024)
• Survodutide Once Weekly for the Treatment of Adults with Obesity (The New England Journal of Medicine, 2026)
• Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity (Diabetes Care, 2024)
• GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis (World Journal of Gastroenterology, 2024)
• Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD (Alimentary Pharmacology & Therapeutics, 2025)
• Novel GLP-1-based Medications for Type 2 Diabetes and Obesity (Endocrine Reviews, 2026)
• Emerging pharmacotherapies for obesity: A systematic review (Pharmacological Reviews, 2025)
• Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (Expert Opinion on Pharmacotherapy, 2024)
• Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis (Hepatology, 2025)
• The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health (Metabolism, 2024)
• Weight management treatment in obesity (Medicina Clinica, 2025)